HTBX News and Press, Heat Biologics Inc. From 04/19/22

The clinical-stage biotech, Heat Biologics (NYSE:HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03. The name change will coincide with a change in the company’s ticker symbol to “NHWK” on the same day. The new name be...

DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today ann...

DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds i...

Heat Biologics (NYSE:HTBX) said its unit Scorpion Biological Services, a private developer, the state of Kansas and local and university affiliates will develop a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas. The company said Man...

500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas today at 11:00am ET/ 10:00am CT today at https://www.kansascommerce.gov/projectannouncement-4-18-22/ DURHAM, N.C....

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today ann...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today unv...

DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces...

Heat Biologics (NYSE:HTBX) has presented favorable survival data at The American Association of Cancer Research of HS-110 in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer. Also, submitted meeting requests to the FDA for separate Type B and Type C meeti...